Literature DB >> 11498153

Induction immunosuppression with interleukin-2 receptor antibodies (basiliximab and daclizumab) in renal transplant recipients.

M P Nair1, M R Nampoory, K V Johny, J N Costandi, M Abdulhalim, W El-Reshaid, I Al-Muzairai, V T Ninan, M Samhan, M Al-Mousawi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11498153     DOI： 10.1016/s0041-1345(01)02184-4

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  11 in total

Review 1.  Immunosuppressive preconditioning or induction regimens : evidence to date.

Authors:  Henkie P Tan; Marc C Smaldone; Ron Shapiro
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 2.  Induction therapy in renal transplantation : an overview of current developments.

Authors:  Gaetano Ciancio; George W Burke; Joshua Miller
Journal:  Drugs       Date:  2007       Impact factor: 9.546

3.  Basiliximab induction in patients receiving tacrolimus-based immunosuppressive regimens.

Authors:  Tainá Veras de Sandes-Freitas; Cláudia Rosso Felipe; Marcello Fabiano de Franco; Hélio Tedesco-Silva; José Osmar Medina-Pestana
Journal:  Int Urol Nephrol       Date:  2012-10-11       Impact factor: 2.370

4.  MnTMPyP, a superoxide dismutase/catalase mimetic, decreases inflammatory indices in ischemic acute kidney injury.

Authors:  Jordan Mortensen; Brian Shames; Christopher P Johnson; Vani Nilakantan
Journal:  Inflamm Res       Date:  2010-12-12       Impact factor: 4.575

5.  Similar survival in patients following heart transplantation receiving induction therapy using daclizumab vs. basiliximab.

Authors:  Spencer T Martin; Tomoko S Kato; Maryjane Farr; Jaclyn T McKeen; Faisal Cheema; Mengxi Ji; Alexandra Ross; Halit Yerebakan; Yoshifumi Naka; Hiroo Takayama; Susan Restaino; Donna Mancini; P Christian Schulze
Journal:  Circ J       Date:  2014-12-12       Impact factor: 2.993

Review 6.  Basiliximab: a review of its use as induction therapy in renal transplantation.

Authors:  Therese M Chapman; Gillian M Keating
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 7.  Interleukin 2 receptor antagonists for kidney transplant recipients.

Authors:  Angela C Webster; Lorenn P Ruster; Richard McGee; Sandra L Matheson; Gail Y Higgins; Narelle S Willis; Jeremy R Chapman; Jonathan C Craig
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

8.  Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  Robert P Baughman; Keith C Meyer; Ian Nathanson; Luis Angel; Sangeeta M Bhorade; Kevin M Chan; Daniel Culver; Christopher G Harrod; Mary S Hayney; Kristen B Highland; Andrew H Limper; Herbert Patrick; Charlie Strange; Timothy Whelan
Journal:  Chest       Date:  2012-11       Impact factor: 9.410

9.  Anti-interleukin-2 receptor antibodies-basiliximab and daclizumab-for the prevention of acute rejection in renal transplantation.

Authors:  Junichiro Sageshima; Gaetano Ciancio; Linda Chen; George W Burke
Journal:  Biologics       Date:  2009-07-13

10.  Standard induction with basiliximab versus no induction in low immunological risk kidney transplant recipients: study protocol for a randomized controlled trial.

Authors:  Aziza Ajlan; Hassan Aleid; Tariq Zulfiquar Ali; Hala Joharji; Khalid Almeshari; Ahmed Mohammed Nazmi; Yaser Shah; Edward Devol; Dalal Alkortas; Zinah Alabdulkarim; Dieter Broering; Ibrahim Alahmadi; Asad Ullah; Anwar Alotaibi; Ahmed Aljedai
Journal:  Trials       Date:  2021-06-24       Impact factor: 2.279
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.